Compound Radar

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

United States · Healthcare / Medical Devices

Price $21.35
Market cap $1.22B
Next earnings Nov 4, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 40
  • Profitability 70
  • Business Quality 75
  • Balance Sheet 45
  • Cash Flow 25

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 75/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices company in the Healthcare sector. Compound Radar rates PROCEPT BioRobotics Corporation 45/100 (Speculative) due to high business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -18.52
  • EV/Revenue 3.42

Profitability

  • Revenue Growth 19.3%
  • Gross Margin 63.4%
  • Operating Margin -32.1%
  • Net Margin -32.5%
  • ROE -30.2%

Financial strength

  • Cash $227.91M
  • Debt $77.50M
  • Net Cash $150.41M
  • Free Cash Flow $-58.34M
  • Current Ratio 6.55

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks PROCEPT BioRobotics Corporation (PRCT).

View Methodology & FAQ →